As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market <li /> Merck e ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business.

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Merck & Co – known as MSD outside the US and Canada – and Exelixis have entered into a clinical development collaboration to evaluate new combination treatments for head and neck cancer and renal cell ...